Levy-Khademi Floris, Irina Shchors, Avnon-Ziv Carmit, Levmore-Tamir Michal, Leder Oren
J Pediatr Endocrinol Metab. 2015 Mar;28(3-4):449-51. doi: 10.1515/jpem-2014-0119.
Congenital hyperinsulinism (CHI) is the most common cause of prolonged hypoglycemia in the neonate. It is caused by several genetic mutations that interfere with the cascade of normal insulin secretion from pancreatic beta cells. Octreotide, a somatostatin analog, suppresses insulin secretion from pancreatic beta cells, and is an effective therapy used for both short and long term in the treatment of CHI. It is well tolerated in most patients; however, several adverse effects have been reported, most of them mild and transient. Impaired liver function has been described previously in few children. Here, we describe about a child with CHI treated with continuous intravenous octreotide who developed cholestasis and hepatitis after a short period of treatment. This combination of liver effects with a short duration of treatment has not been reported previously with octreotide use in this population.
先天性高胰岛素血症（CHI）是新生儿持续性低血糖最常见的原因。它由多种基因突变引起，这些突变会干扰胰腺β细胞正常胰岛素分泌的级联反应。奥曲肽是一种生长抑素类似物，可抑制胰腺β细胞分泌胰岛素，是治疗CHI的短期和长期有效疗法。大多数患者对其耐受性良好；然而，也有一些不良反应的报道，其中大多数是轻微和短暂的。此前曾有少数儿童出现肝功能受损的描述。在此，我们描述了一名接受持续静脉注射奥曲肽治疗的CHI患儿，在短期治疗后出现胆汁淤积和肝炎。在该人群中使用奥曲肽治疗时，这种短时间治疗就出现肝脏影响的情况此前尚未见报道。
